Profitelligence Profitelligence · Filing Ledger Open MRK research →

Form 8-K · Current Report · Filed 2025-09-09

Merck & Co., Inc. Issued New Notes

On September 9, 2025, Merck & Co., Inc. closed an underwritten public offering of various notes totaling $500,000,000 to $1,750,000,000 in aggregate principal amount, due between 2027 and 2055. The issuance was conducted under the Company's Registration Statement on Form S-3ASR and an indenture dated January 6, 2010.

Filer
Merck & Co., Inc. MRK · NYSE
Filed
Accession
0000310158-25-000047
CIK
0000310158
Signal
Low impactHealthcare

Items reported

Item 8.01

Other Events

Corporate Update
Item 9.01

Financial Statements and Exhibits

Exhibits Furnished

Market reaction

Close before filing

$84.09

Next session

-0.1%

Since filing

+54.8%

Latest close

$130.20

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from MRK reporting the same item, with the next session's move:

About Merck & Co., Inc.

Merck & Co., Inc. is a prominent player in the global pharmaceutical industry. It is primarily focused on the research, development, production, and marketing of drugs and vaccines. Known for its strong emphasis on innovative health solutions, Merck develops treatments and vaccines for a variety of diseases affecting humans and animals. Key areas include oncology, infectious diseases, diabetes, and vaccines, reflecting its commitment to addressing critical health challenges worldwide. The company operates in several strategic regions, exporting its advanced therapies to meet healthcare needs across different markets. With a robust pipeline of new products and significant investment in research and development, Merck plays a vital role in advancing medical breakthroughs and enhancing patient care. Beyond pharmaceuticals, Merck is involved in animal health, providing veterinary vaccines and services, contributing to agricultural productivity and food security. The company's ongoing efforts in groundbreaking research and public health initiatives underscore its importance in the healthcare sector.

Exchange NYSE Industry Drug Manufacturers - General Company website ↗

Never miss another MRK filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts